Avalon GloboCare (NASDAQ:ALBT) Releases Earnings Results

Avalon GloboCare (NASDAQ:ALBT) issued its quarterly earnings results on Monday. The company reported ($0.49) EPS for the quarter, Zacks reports.

Avalon GloboCare Stock Performance

Avalon GloboCare stock remained flat at $0.40 during midday trading on Monday. The company’s stock had a trading volume of 423,324 shares, compared to its average volume of 5,157,586. Avalon GloboCare has a 1 year low of $0.34 and a 1 year high of $4.74. The firm’s 50 day moving average is $0.60 and its 200-day moving average is $1.07. The firm has a market cap of $3.33 million, a PE ratio of -0.11 and a beta of -0.04.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Avalon GloboCare in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Avalon GloboCare has a consensus rating of “Sell”.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.